Union Health Minister Shri J.P. Nadda Launches Annual Nationwide Mass Drug Administration Campaign for Lymphatic Filariasis Elimination across 12 Endemic States

1. At a Glance

• Annual Mass Drug Administration (MDA) campaign launched by Union Health Minister J.P. Nadda via video conference on 10 February 2026 across 12 LF-endemic States [1].
• Anchors India's pledge to eliminate Lymphatic Filariasis (LF) by 2027, three years ahead of the SDG 2030 target [1][3].
• Relevant for UPSC under Health (GS-II), vector-borne NTDs (GS-III S&T), and cooperative federalism in public health delivery.

2. Why in the News

• On 10 Feb 2026, Shri J.P. Nadda flagged off the annual nationwide MDA round, calling for a "Whole-of-Government and Whole-of-Society" approach to a Filariasis-Free India by 2027 [1].
• Round covers 124 districts (55 DA + 69 IDA) across 719 blocks in 12 States [1].
• Follows the Feb 2025 launch by Nadda across 13 endemic states and the Aug 2024 bi-annual second phase under MoS Prataprao Jadhav [4].

3. Background & Evolution

• 1955: National Filaria Control Programme launched [2].
• 1997: WHO Resolution WHA 50.29 to eliminate LF as a public health problem [2].
• 2004: India launched the Elimination of Lymphatic Filariasis (ELF) Programme with single-dose DEC [2].
• 2007: Shift to DA regimen — Diethylcarbamazine (DEC) + Albendazole co-administration [2].
• 2018: Triple-drug therapy (IDA) — Ivermectin + DEC + Albendazole — introduced per WHO recommendation [3][2].
• Dec 2023: IDA-MDA implemented in 63 LF-endemic districts [3].
• 2023: India set 2027 elimination target (ahead of SDG 3.3, 2030) [3].

4. Core Static Facts

• Disease: Lymphatic Filariasis (elephantiasis); caused by parasitic worms Wuchereria bancrofti, Brugia malayi, B. timori; transmitted by Culex mosquito (primarily).
• Nodal body: National Center for Vector Borne Diseases Control (NCVBDC) under Ministry of Health & Family Welfare (MoHFW) [2].
• National goal: Elimination by 2027 [1][3].
• Endemic burden (national): ~257 districts in 21 States/UTs; population at risk ~650 million; eligible for treatment ~500 million [2].
• 2026 round scope: 12 States, 124 districts (55 DA + 69 IDA), 719 blocks [1].
• Two strategy pillars: (i) MDA for transmission interruption; (ii) MMDP — Morbidity Management & Disability Prevention (home-based lymphoedema care + hydrocele surgery) [2].
• Elimination threshold: Microfilaria (Mf) prevalence rate <1% in all endemic areas [1].
• Validation tool: Transmission Assessment Survey (TAS) in school children after ≥5 MDA rounds [2].
• Campaign brand: "Sarva Dawa Sevan" [4].

5. Multi-Dimensional Analysis

Social / Equity

• LF disproportionately affects poor, rural populations; causes lifelong disability and social stigma (esp. lymphoedema, hydrocele) [2].
• "Whole-of-Society" mobilisation: Panchayats, ASHAs, frontline workers central to last-mile coverage [1].

Scientific / Technological

• Shift from DA to IDA triple-therapy demonstrably superior: clears microfilariae and sterilises adult worms [3].
• Economic analysis: ICER ~US$17 per DALY averted; projected savings US$66.92 million vs DA [3].

Administrative / Federalism

• Health is a State Subject (List II, Entry 6); centre-state video-conference launch with State Health Ministers showcases cooperative-federalism delivery model [1].
• Mission-Mode MDA at block level introduced to plug coverage gaps [3].

Geopolitical / Global Health

• India contributes the largest share of global LF burden; meeting 2027 target is pivotal to WHO's NTD Road Map 2021–2030 [3].

6. Recent Developments (last 12-18 months)

• Aug 2024: MoS Prataprao Jadhav launches second phase of bi-annual MDA 2024 [4].
• Feb 2025: J.P. Nadda launches MDA round across 13 endemic states [4].
• 10 Feb 2026: Nadda launches annual MDA across 12 endemic states, 124 districts, 719 blocks [1].

7. Prelims Hooks

• LF elimination target year for India: 2027 (SDG global target: 2030) [1][3].
• Implementing body: NCVBDC (formerly NVBDCP) under MoHFW [2].
• IDA = Ivermectin + DEC + Albendazole; DA = DEC + Albendazole [3].
• Triple-drug regimen (IDA) introduced in India in 2018 on WHO recommendation [3].
• Primary causative parasite in India: Wuchereria bancrofti (~99% cases); vector: Culex quinquefasciatus.
• WHO resolution mandating LF elimination: WHA 50.29 (1997) [2].
• India's National Filaria Control Programme launched in 1955 [2].
• 2026 MDA campaign scope: 12 States / 124 districts / 719 blocks [1].
• Mf prevalence elimination threshold: <1% [1].
• Validation survey: Transmission Assessment Survey (TAS) [2].
• Two pillars: MDA + MMDP [2].
• Campaign tagline: "Sarva Dawa Sevan" [4].

8. Mains Relevance

• GS-II: Issues relating to development & management of Social Sector — Health.
• GS-III: Science & Technology — disease eradication, indigenous drug delivery.
• Probable stems: 1. "Despite three decades of MDA, lymphatic filariasis persists in India. Examine the bottlenecks and evaluate the IDA strategy in meeting India's 2027 elimination goal." (GS-II, 250 words) 2. "Elimination of neglected tropical diseases requires a whole-of-society approach. Discuss with reference to India's LF programme." (GS-II) 3. "Compare India's LF elimination architecture with its earlier successes against smallpox and polio." (GS-II)

9. Related Topics to Study Next

• National Center for Vector Borne Diseases Control (NCVBDC) — umbrella body for malaria, dengue, kala-azar, JE, LF.
• WHO NTD Road Map 2021-2030 — global benchmark.
• Kala-azar elimination — India achieved sub-elimination threshold; comparable trajectory.
• National Health Mission (NHM) — funding/implementation backbone.
• Ayushman Bharat – Health & Wellness Centres — last-mile delivery node for MMDP.
• SDG 3 (Good Health & Well-being) — Target 3.3 on NTDs.
• Polio eradication in India (2014 certification) — successful MDA-style model.
• One Health approach — vector-borne disease control linkages.

10. Common Errors / Trap Areas

• Eradication vs Elimination: India aims to eliminate LF as a public health problem (Mf<1%), not eradicate it. Smallpox is the only human disease eradicated.
• Nodal body confusion: It is NCVBDC (renamed from NVBDCP in 2023), under MoHFW — not ICMR or MoEFCC.
• Drug regimen mix-up: DA (2-drug) vs IDA (3-drug, adds Ivermectin). Don't confuse with DEC alone (pre-2007).
• Vector: LF is primarily transmitted by Culex, not Anopheles (malaria) or Aedes (dengue).
• Target year: India's 2027 ≠ global SDG 2030.
• 2026 round covers 12 states; the 2025 round covered 13 — don't conflate.